A new poly(I:C)-decorated PLGA-PEG nanoparticle promotes Mycobacterium tuberculosis fusion protein to induce comprehensive immune responses in mice intranasally

Du, Xiufen; Tan, D. S. K.; Gong, Yang; Zhang, Yifan; Han, Jiangyuan; Lv, Wei; Xie, Tao; He, Pu; Hou, Zongjie; Xu, Kun; Tan, Jiying; Zhu, Bin

doi:10.1016/j.micpath.2021.105335

Cited by 6 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Respiratory immunization with a DNA vaccine prepared with chitosan can protect tuberculosis by enhancing the production of SIgA in lung bronchoalveolar lavage fluid (BALF) [ 75 , 76 ]. NP, a potential new nanoparticle adjuvant of the tuberculosis subunit vaccine, can also increase SIgA and other immune proteins in lung lavage fluid to induce strong cellular and humoral immune responses [ 77 ]. Mice with reduced IgA and pIgR levels were more susceptible to BCG infection [ 78 ].…”

Section: The Relationship Between Siga and Pulmonary Diseasesmentioning

confidence: 99%

SIgA in various pulmonary diseases

Wang,

Zhang,

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Secretory immunoglobulin A (SIgA) is one of the most abundant immunoglobulin subtypes among mucosa, which plays an indispensable role in the first-line protection against invading pathogens and antigens. Therefore, the role of respiratory SIgA in respiratory mucosal immune diseases has attracted more and more attention. Although the role of SIgA in intestinal mucosal immunity has been widely studied, the cell types responsible for SIgA and the interactions between cells are still unclear. Here, we conducted a wide search of relevant studies and sorted out the relationship between SIgA and some pulmonary diseases (COPD, asthma, tuberculosis, idiopathic pulmonary fibrosis, COVID-19, lung cancer), which found SIgA is involved in the pathogenesis and progression of various lung diseases, intending to provide new ideas for the prevention, diagnosis, and treatment of related lung diseases.

show abstract

Section: The Relationship Between Siga and Pulmonary Diseasesmentioning

confidence: 99%

SIgA in various pulmonary diseases

Wang,

Zhang,

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…CAF01 is a TDM analog comprising DDA. TDB has been displayed to stimulate Th1‐type cellular immunological responses 106 . The emulsion and liposomal adjuvants both protected against a mycobacterial challenge in preclinical studies, but the liposomes‐based (AS01) induced a stronger immune response.…”

Section: Liposomal Subunit Vaccines Against Tbmentioning

confidence: 99%

“…TDB has been displayed to stimulate Th1-type cellular immunological responses. 106 The emulsion and liposomal adjuvants both protected against a mycobacterial challenge in preclinical studies, but the liposomes-based (AS01) induced a stronger immune response. This was determined by a stronger IFN-γ response, as well as a contribution from CD8+ T cells.…”

Section: Liposomal Subunit Vaccines Against Tbmentioning

confidence: 99%

Liposomal delivery system/adjuvant for tuberculosis vaccine

Moradi

Vahedi

Abbassioun

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

As reported by the World Health Organization, about 10 million individuals were infected with tuberculosis (TB) worldwide. Moreover, approximately 1.5 million people died of TB, of which 214,000 were infected with HIV simultaneously. Due to the high infection rate, the need for effective TB vaccination is highly felt. Until now, various methodologies have been proposed for the development of a protein subunit vaccine for TB. These vaccines have shown higher protection than other vaccines, particularly the Bacillus culture vaccine. The delivery system and safety regulator are common characteristics of effective adjuvants in TB vaccines and the clinical trial stage.The present study investigates the current state of TB adjuvant research focusing on the liposomal adjuvant system. Based on our findings, the liposomal system is a safe and efficient adjuvant from nanosize to microsize for vaccinations against TB, other intracellular infections, and malignancies. Clinical studies can provide valuable feedback for developing novel TB adjuvants, which ultimately enhance the impact of adjuvants on next-generation TB vaccines.

show abstract